Big take home points Funding till next year confirmed, so we can...

Big take home points

Funding till next year confirmed, so we can except a CR around OCT-DEC Total current assets at year-end stand at $7,514,175.

Confirmed discussions with big pharma as we have been saying for months

Confirmed strategy of funding only to next milestones or inflection points, not the full amount

Confirmed next trial is a registration trial

Confirmed monies being spent on FDA requirement for next study, IE animal studies and manufacturing

Confirmed expectations of hearing data from other studies this year as well.....again as we have all being saying

All in all nothing surprising except their cost cutting as been slashed by over 40% in the last two years while increasing their R&D. excalty what you expect from a team focused on results.